Environmental

R&D intensity near revenue is materially higher than many medtech peers, supporting product innovation but also indicating a resource-intensive operating model versus leaner competitors.

No direct emissions, energy, or waste disclosures were provided, limiting evidence of environmental management relative to peers and keeping the assessment anchored to capital intensity.

Negative gross margin suggests the current cost structure is less efficient than peers, which can indirectly increase environmental footprint per unit of output if not offset by scale.

The available metrics do not show a clear environmental leadership position versus peers, but they also do not indicate a structurally worse environmental profile than similarly early-stage medtech companies.

Social

Stock-based compensation is extremely high relative to revenue, which can support talent retention but also signals heavy dilution pressure compared with more mature peers.

No workforce, safety, product quality, or customer outcome disclosures were provided, limiting visibility into core social risks that are material for a medical technology company.

High R&D spend relative to revenue can support patient-facing innovation, but the absence of clinical, access, or post-market evidence prevents a stronger peer-relative social assessment.

The disclosed metrics suggest a development-stage profile with mixed social implications, leaving LUCD broadly in line with peers rather than clearly advantaged.

Governance

Stock-based compensation at more than four times revenue points to weak capital discipline versus peers, because compensation intensity appears high relative to current operating scale.

Debt metrics are not alarming, with net debt to EBITDA low, but the debt-to-equity ratio remains elevated versus conservatively financed peers.

The lack of board, audit, ownership, or controversy data limits confidence in governance quality, so the score relies mainly on observable capital-allocation signals.

Overall governance appears adequate but not strong relative to peers, as dilution and financing structure offset any benefit from manageable leverage.

Overall Score

LUCD screens as a moderate ESG performer versus peers, with innovation support offset by weak capital discipline and limited disclosure across all three pillars.

Score Driver: Extremely High Stock-Based Compensation Relative To Revenue Is The Most Decisive Peer-Negative Governance Signal.